Literature DB >> 3062507

Radiolabelled granulocytes in inflammatory bowel disease: diagnostic possibilities and clinical indications.

W Becker1, W Fischbach, M Weppler, B Mosl, G Jacoby, W Börner.   

Abstract

Radiolabelled granulocytes in chronic inflammatory bowel diseases (CIBD) are able to diagnose the disease extent and assess the disease activity. It may be performed with 111In oxine- and 99Tcm hexamethylpropyleneamineoxime (HMPAO)-labelled cells. The granulocyte scan localizes inflamed bowel segments with an accuracy comparable with radiology and endoscopy including biopsy of the bowel (r = 0.95; P less than 0.001). The specificity of the scan for diseased segments is near 100%, the sensitivity 92%. A three-phase white blood cell scan (imaging: 0.5, 4, 20 h post injection) allows differentiation of diseased bowel segments from abscesses and fistulas. False positive results are possible in necrotic carcinomas. The 99Tcm HMPAO scan shows rapid renal and delayed biliary and intestinal excretion of tracer. In this way diagnostic problems arise in the small pelvis. Because of the intestinal and biliary excretion, early images should be obtained (0.5-2 h post injection). Later scans with 99Tcm HMPAO are of minor importance. The disease activity can very specifically be assessed by the determination of the percentage faecal 111In excretion (96 h faecal collection). Active and non-active diseases can be clearly differentiated. We found no correlation with the subjectively influenced Crohn's disease activity index (CDAI) (r = 0.25; P greater than 0.05), but good correlations with the Dutch Index (van Hees: r = 0.67), ESR (r = 0.69), serum albumin (r = -0.54) and orosomucoid (r = 0.65). The percentage faecal excretion correlates well with the histologically estimated leucocytic bowel infiltration. Because of the intestinal 99Tcm HMPAO excretion the determination of faecal excretion is pointless in 99Tcm studies.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3062507     DOI: 10.1097/00006231-198810000-00004

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  10 in total

1.  Technetium-99m hexamethyl propylene amine oxine leucocytes in the assessment of disease activity in inflammatory bowel disease.

Authors:  E Lantto; K Järvi; I Krekelä; T Lantto; M Taavitsainen; H Vedenkangas; M Vorne
Journal:  Eur J Nucl Med       Date:  1992

2.  Validation of Neutrophil CD64 Blood Biomarkers to Detect Mucosal Inflammation in Pediatric Crohn's Disease.

Authors:  Phillip Minar; Kimberly Jackson; Yi-Ting Tsai; Heidi Sucharew; Michael J Rosen; Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2017-12-19       Impact factor: 5.325

3.  Comparison of simultaneous 99mTc-HMPAO and 111In oxine labelled white cell scans in the assessment of inflammatory bowel disease.

Authors:  R A Allan; G E Sladen; S Bassingham; C Lazarus; S E Clarke; I Fogelman
Journal:  Eur J Nucl Med       Date:  1993-03

4.  Labelled leucocyte scintigraphy in inflammatory bowel disease: clinical applications.

Authors:  M H Giaffer
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

5.  Quantitative assessment of overall inflammatory bowel disease activity using labelled leucocytes: a direct comparison between indium-111 and technetium-99m HMPAO methods.

Authors:  J C Mansfield; M H Giaffer; W B Tindale; C D Holdsworth
Journal:  Gut       Date:  1995-11       Impact factor: 23.059

6.  Quantification of inflammatory bowel disease activity using technetium-99m HMPAO labelled leucocyte single photon emission computerised tomography (SPECT).

Authors:  M J Weldon; A M Masoomi; A J Britten; J Gane; C J Finlayson; A E Joseph; J D Maxwell
Journal:  Gut       Date:  1995-02       Impact factor: 23.059

7.  Granulocyte-specific monoclonal antibody technetium-99m-BW 250/183 and indium-111 oxine-labelled leucocyte scintigraphy in inflammatory bowel disease.

Authors:  I Segarra; M Roca; C Baliellas; L Vilar; Y Ricart; J Mora; R Puchal; J Martin-Comin
Journal:  Eur J Nucl Med       Date:  1991

Review 8.  The contribution of nuclear medicine to the patient with infection.

Authors:  W Becker
Journal:  Eur J Nucl Med       Date:  1995-10

9.  Technetium-99m scintigraphy: more accurate assessment of ulcerative colitis with exametazime-labelled leucocytes than with antigranulocyte antibodies.

Authors:  S Almers; G Granerus; L Franzén; M Ström
Journal:  Eur J Nucl Med       Date:  1996-03

10.  Anti-granulocyte immunoscintigraphy and [99mTc]hexamethylpropyleneamine-oxime-labeled leukocyte scintigraphy in inflammatory bowel disease.

Authors:  M Papos; F Nagy; G Narai; M Rajtar; G Szantai; J Lang; L Csernay
Journal:  Dig Dis Sci       Date:  1996-02       Impact factor: 3.199

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.